Please assess the completion status of the following clinical trial:

Trial Title: Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* aged between 18 and 45 years inclusive~* have a clinical diagnosis of chronic cyclical pelvic pain of at least 6 months duration (with or without evidence of endometriosis)~* have had investigations for possible endometriosis within three years prior to screening visit~* had regular menstrual cycles (24-42 days) for 3 months prior to screening~* treatment with LHRHa is indicated~* must be able to understand and be willing to comply with the requirements of the protocol~Exclusion Criteria:~* treated with any LHRHa within 6 months prior to screening~* treated with danazol, gestrinone or cyproterone acetate within 6 months prior to screening~* used cyclical progesterones or combined oral contraceptives within one full menstrual cycle prior to screening~* treated with any other medication other than analgesics within 3 months prior to screening~* continuous or acyclical pelvic pain~* known metabolic bone disease~* abnormal full blood count or liver or renal function at screening or within 6 months~* unexplained vaginal bleeding~* bone mineral density age adjusted T Score of -2 or below at screening visit.~* any other medical condition or abnormality that would impact on the safety or efficacy of the study treatment~* receiving treatment with coumarin or indanedione derivatives~* known contraindication or allergy or hypersensitivity to test compounds~* pregnancy or lactation~* planning a pregnancy within 31 months of screening~* of child bearing potential and unwilling to use adequate barrier contraception for the duration of the study~* received any investigational drug therapy within 30 days prior to the study~* has previously entered the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).